ATRA Stock Overview
Engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Atara Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.53 |
| 52 Week High | US$19.00 |
| 52 Week Low | US$5.01 |
| Beta | 0.32 |
| 1 Month Change | -23.72% |
| 3 Month Change | -55.08% |
| 1 Year Change | -67.40% |
| 3 Year Change | -97.14% |
| 5 Year Change | -97.30% |
| Change since IPO | -98.16% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop
Mar 07
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Jan 21Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jan 16Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?
Jan 07Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Nov 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Sep 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Jul 21Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Jul 03New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
May 14Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
May 11Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Feb 06Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
Oct 17Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive
May 18Shareholder Returns
| ATRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.5% | 1.3% | 5.8% |
| 1Y | -67.4% | -11.3% | 4.8% |
Return vs Industry: ATRA underperformed the US Biotechs industry which returned -11.3% over the past year.
Return vs Market: ATRA underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| ATRA volatility | |
|---|---|
| ATRA Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ATRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATRA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 153 | Cokey Nguyen | www.atarabio.com |
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. Fundamentals Summary
| ATRA fundamental statistics | |
|---|---|
| Market cap | US$32.40m |
| Earnings (TTM) | -US$85.40m |
| Revenue (TTM) | US$128.94m |
0.3x
P/S Ratio-0.4x
P/E RatioIs ATRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRA income statement (TTM) | |
|---|---|
| Revenue | US$128.94m |
| Cost of Revenue | US$168.74m |
| Gross Profit | -US$39.80m |
| Other Expenses | US$45.60m |
| Earnings | -US$85.40m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.58 |
| Gross Margin | -30.87% |
| Net Profit Margin | -66.23% |
| Debt/Equity Ratio | 0% |
How did ATRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 12:12 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atara Biotherapeutics, Inc. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Yigal Nochomovitz | Citigroup Inc |
| Michael King | Citizens JMP Securities, LLC |